Shandong Sipond Pharmaceutical Co., Ltd.

Primary Objective: This study used valsartan-amlodipine tablets (I) (80 mg valsartan and 5 mg amlodipine per tablet), certified by Shandong Sibangde Pharmaceutical Co., Ltd., as the test formulation, and valsartan-amlodipine tablets (I) (brand name: Bebopter®, 80 mg valsartan and 5 mg amlodipine per tablet), certified by Novartis Pharma Schweiz AG, as the reference formulation, to conduct a human bioequivalence study under fasting and postprandial conditions to evaluate the bioequivalence of the test and reference formulations in healthy participants. Secondary Objective: To observe the safety of the test and reference formulations in healthy participants.

Primary objective: To investigate the absorption rate and extent of the test preparation and the reference preparation under fasting and postprandial conditions after oral administration of a single dose of gliclazide sustained-release tablets (test preparation T, produced by Shandong Sibonde Pharmaceutical Co., Ltd., trade name: Pumeikang®, specification: 30 mg) and gliclazide sustained-release tablets (reference preparation R, produced by Servier (Tianjin) Pharmaceutical Co., Ltd., trade name: Dameikang®, specification: 30 mg) to healthy subjects, and to evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary objective: To observe the safety of the test preparation gliclazide sustained-release tablets (Pumekang®) and the reference preparation gliclazide sustained-release tablets (Damekang®) in healthy subjects.

Main study objectives After oral administration of a single dose of metformin hydrochloride extended-release tablets (test preparation T, produced by Shandong Sibonde Pharmaceutical Co., Ltd., trade name: Sanbond, specification: 0.5g/tablet) and metformin hydrochloride extended-release tablets (reference preparation R, produced by Merck KGaA, packaged by Merck Pharmaceuticals (Jiangsu) Co., Ltd., trade name: GLUCOPHAGE XR®, specification: 0.5g/tablet) to healthy subjects in the fasting/postprandial state, the absorption rate and degree of the test preparation and the reference preparation under fasting and postprandial conditions were investigated to evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary study objectives Observe the safety of the test preparation metformin hydrochloride extended-release tablets (Sanbond®) and the reference preparation metformin hydrochloride extended-release tablets (GLUCOPHAGE XR®) in healthy subjects after oral administration of a single dose in the fasting/postprandial state.